Oncolytics Biotech Inc.
Elsewhere, Oncolytics Biotech Inc. (Nasdaq) jumped 23 cents, or
14%, to $1.86. The company said it had completed an initial production
run of Reolysin, a potential cancer therapeutic. The treatment is based
on a human reovirus and is designed to target and destroy cancer cells,
either alone or combined with radiation or chemotherapy. "Reolysin
is a cancer therapeutic but it is different than all the other drugs
that are out there and being developed," said Reni Benjamin, an
analyst at Rodman & Renshaw. "This is still a product being
evaluated in clinical trials but there is some potential for this
product as a therapy," Benjamin said. "With the clinical
results reported to date and the expected initiation of our pivotal
program this year, keeping pace with the manufacturing process is
critical," said Dr. Matt Coffey, chief operating officer of
Oncolytics. Oncolytics' clinical program includes a variety of
Phase 1 and Phase 2 human trials using Reolysin.